Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Visaka Industries Limited - Shareholders meeting

2018-06-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
509055 VISAKAIND

0
Visaka Industries Limited - Updates

2018-06-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
509055 VISAKAIND

0
Visaka Industries Limited - Updates

2018-05-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
509055 VISAKAIND

0
Visaka Industries Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-15 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
509055 VISAKAIND

0
Visaka Industries Limited - Dividend

2018-05-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
509055 VISAKAIND

0
Visaka Industries Limited - AGM/Book Closure

2018-05-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
509055 VISAKAIND

0
Visaka Industries Limited - Financial Result Updates

2018-05-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
509055 VISAKAIND

0
Visaka Industries Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
509055 VISAKAIND

39
Closing Bell: Sensex ends 200 pts higher, Nifty closes above 10,600; PSU banks fall

2018-04-26 moneycontrol
3:30 pm Market at Close: Shares have ended the day on a strong note, with the Sensex rising over 200 points, while the Nifty is above 10,600-mark.The market breadth is negative as 1102 shares advanced against a decline of 1507 shares, while 177 shares were unchanged.
RMGALLOY 500408 500325 VISAKAIND 532832 534816 500134 500570 RLNIY UNIPLY AXB RELCAPITAL YYBKY STS AXBA ROHLTD 500180 534809 TCS PCJEWELLER IBREALEST RALLIS BHRYY 533150 RELIANCE NFL BHRQY TTNQY 532699 532215 SHAHALLOYS SPMWY EQMNY 532540 AXISBANK RIGD SUPREMEIND 500355 INFRATEL HDFCBANK BHARTIARTL TATAMOTORS 503100 523630 500111 YESBANK 517354 HVLQY PHOENIXLTD IBN ESSAROIL 532648 513436 532646 TAKE AXBKY 532454 ICICIBANK GODREJPROP 532890 HDB 532174 500365 HAVELLS TATAELXSI 509055 509930 TTM

14
Market Live: Nifty eyes 10,600 ahead of expiry; Realty index outshines after Mumbai Development Plan

2018-04-26 moneycontrol
10:45 am Buzzing: Shares of Mahindra & Mahindra Financial Services touched a 52-week high of Rs 532, rising 4.8 percent on the back of robust Q4 numbers.
500408 RALLIS 533150 VISAKAIND 532832 532699 532215 SHAHALLOYS EQMNY AXISBANK 500355 503100 500111 YESBANK UNIPLY AXB PHOENIXLTD RELCAPITAL 532648 YYBKY 513436 532646 AXBKY AXBA GODREJPROP ROHLTD 509055 TATAELXSI IBREALEST

14
Market Live: Nifty inching towards 10,600 ahead of expiry; Wipro falls 4% post Q4 nos

2018-04-26 moneycontrol
9:38 am Market Update: The market traded mildly higher amid consolidation ahead of expiry of April derivative contracts today.
YESBANK 500408 RALLIS UNIPLY RELCAPITAL AXB 532648 YYBKY VISAKAIND 532646 532699 532215 AXBKY AXBA EQMNY ROHLTD AXISBANK 500355 509055 TATAELXSI 500111

0
Visaka Industries Limited - Investor Presentation

2018-04-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
509055 VISAKAIND

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...